From PsychonautWiki
(Redirected from 2C-D-NBOMe)
Jump to: navigation, search

Skull and crossbones darktextred2.png

Members of the NBOH series can easily be fatal at higher doses.

It is strongly discouraged to take high doses of these substances or to insufflate (snort) them. Please see this section for more details.

Summary sheet: 25D-NBOMe
Chemical Nomenclature
Common names 25D-NBOMe
Substitutive name 2C-D-NBOMe
Systematic name 1-2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 300 µg
Light 300 - 800 µg
Common 800 - 1000 µg
Strong 1000 - 1200 µg
Heavy The NBOMe series can be fatal at heavy doses.[1][2][3]
Total 4 - 6 hours
Onset 20 - 40 minutes
Peak 1 - 2 hours
Offset 1 - 2 hours
After effects > 6 hours
Heavy The NBOMe series can be fatal when insufflated.[1][2][3] It is strongly discouraged.

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

25D-NBOMe (also known as 2C-D-NBOMe, and N-Bomb, although this is commonly used to refer to to many members of the 25x-NBOMe series) is novel synthetic psychedelic substance of the phenethylamine chemical class. It produces an array of primarily visual and stimulating psychedelic effects when administered.

The name 25D-NBOMe, which short-hand for 2C-D-NBOMe, is a derivative of the phenethylamine psychedelic 2C-D. It was first synthesized in 2011 by Martin Hansen[4] and subsequently had its activity explored in 2012 and 2014, where it was established to be a potent agonist at the 5-HT2A receptor that produces effects similar to other members of the 25x-NBOMe series.[5][6]

It is worth noting that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and letting it absorb into one's mouth over a period of 15-25 minutes. 25D-NBOMe can also be vaporized and inhaled to cause significantly more rapid and powerful effects as well as a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range as well as having a low therapeutic index.

This substance had no history of human use before being sold online as a designer drug in 2010.[citation needed] Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25D-NBOMe in humans, and its closely related analogs like 25I-NBOMe has been associated with many deaths and hospitalizations.[citation needed] Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.


25D-NBOMe, or 2C-D-NBOMe, is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-D. 25D-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4. It differs from 2C-D structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25D-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.


25D-NBOMe has efficacy at the 5-HT2A receptor where it acts as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. The addition of the NBOMe group to the structure results in a sixteen-fold increase in potency when compared to 2C-D, allowing even the most extreme of doses to fit in liquid form onto tabs and blotter paper, which people often mistake for LSD.

Subjective effects

{The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects

Toxicity and harm potential

25D-NBOMe is a very new substance, and very little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined.[7] Due to 25D-NBOMe's extreme potency, it should not be insufflated (snorted) as this method of administration appears to have led to several deaths from other NBOMe compounds in the past year.[8]

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

In terms of its addictive potential, 25D-NBOMe has not been studied formally but many users experience a self-regulating quality. Also, due to its immediate tolerance build up, which lasts up to 2 - 3 weeks after the experience, it is difficult to use this substance compulsively.

Dangerous interactions

Although many psychoactive substances are safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The following lists some known dangerous combinations, but may not include all of them. A combination that appears to be safe in low doses can still increase the risk of injury or death. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume.


  • Austria: 25D-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[10]
  • Sweden: 25D-NBOMe is classed as Schedule I[11]
  • United Kingdom - 25D-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[12]
  • Latvia: 25D-NBOMe is a Schedule I controlled substance.[13]
  • Canada: 25D-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[14]

See also

External links


  1. 1.0 1.1 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  2. 2.0 2.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  3. 3.0 3.1 Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
  4. Hansen, M. Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. PhD Thesis, University of Copenhagen, 2011. | https://bitnest.netfirms.com/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V
  5. Casale, John F.; Hays, Patrick A. (2012). "Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I" (PDF). Microgram Journal. 9 (2): 84–109. Retrieved 14 January 2014.
  6. Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMC 3963123 Freely accessible. PMID 24397362. https://doi.org/10.1021/cn400216u
  7. "Fatalities / Deaths". Erowid. April 26 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  8. http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/
  9. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  10. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  11. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
  12. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
  13. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  14. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28